Iraqi Registry Data Proves Safety and Efficacy of switching to Adalimumab Biosimilar in Treating Rheumatoid Arthritis

  Background: Adalimumab is approved for Rheumatoid Arthritis (RA). In 2021, A biosimilar (ABP501;Amgevita®) was licensed in Iraq. The current study aimed to ensure safety and Efficacy of Amgevita in RA Patients in Iraq. Patients and Methods: A Cross sectional Observational study Started on 69...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Yasameen Abbas, Nabaa Ihsan, Asal Adnan, Marwa Moayad, Ali AlKazzaz, Avin Maroof, Ali Abdulrahman, Nazar Abdulateef, Mohammad AlOsami, Faiq Gorial, Mohammed Altahhan, Zahraa Almansi, Ali Alnoori
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	University of Baghdad/ Al-Kindy College of Medicine 2024-12-01
סדרה:	مجله كليه طب الكندي
נושאים:	Rheumatoid arthritis Biosimilar Adalimumab
גישה מקוונת:	https://jkmc.uobaghdad.edu.iq/index.php/MEDICAL/article/view/1476
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!